These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21740818)

  • 1. Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease.
    Li WJ; Zhang HY; Miao CL; Tang RB; DU X; Shi JH; Ma CS
    Chin Med J (Engl); 2011 May; 124(10):1569-72. PubMed ID: 21740818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cigarette smoking on platelet aggregation.
    Pamukcu B; Oflaz H; Onur I; Cimen A; Nisanci Y
    Clin Appl Thromb Hemost; 2011; 17(6):E175-80. PubMed ID: 21406413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets.
    O'Kane PD; Reebye V; Ji Y; Stratton P; Jackson G; Ferro A
    J Mol Cell Cardiol; 2008 Aug; 45(2):223-9. PubMed ID: 18606420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2009 Nov; 124(5):588-91. PubMed ID: 19631365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
    Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
    Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Am J Cardiol; 2005 Oct; 96(8):1095-9. PubMed ID: 16214444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
    Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
    Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease.
    Schwedhelm E; Bierend A; Maas R; Trinks R; Kom GD; Tsikas D; Böger RH
    J Thromb Haemost; 2010 Dec; 8(12):2662-70. PubMed ID: 20961392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study].
    Skowasch D; Lentini S; Andrié R; Jabs A; Bauriedel G
    Dtsch Med Wochenschr; 2001 Jun; 126(24):707-11. PubMed ID: 11446026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients].
    Addad F; Hassine M; Ben Farhat M; Abderrazak F; Chakroun T; Gamra H; Hamdi S; Betbout F; Samama M; Elalamy I
    Arch Mal Coeur Vaiss; 2005 Oct; 98(10):979-83. PubMed ID: 16294543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.